Key Highlights
● Charles River touched a 52-week high of $303.33, the second-best S&P 500 performer after PTC.
● Life-science tools peers Thermo Fisher, Danaher and Illumina rallied alongside it.
● Big drugmakers dragged on health care: Merck was the worst Dow stock and Bristol-Myers Squibb fell after a downgrade.
Charles River Laboratories rallied to a 52-week high on Monday, Oct. 5, finishing as the second-best performer in the S&P 500 as life-science tools stocks bucked a weak day for health care.
A standout in a soft sector
Charles River Laboratories (NYSE:CRL) climbed sharply on Monday, touching a 52-week high of $303.33. Only PTC, which agreed to a takeover, did better among S&P 500 members.
The move was striking because health care as a whole struggled. The sector was the weakest in the index at midday, and by the close it had posted a modest decline. Big drugmakers did much of the damage: Merck (NYSE:MRK) was the worst stock in the Dow, Bristol-Myers Squibb (NYSE:BMY) slid after a downgrade from Leerink Partners, and Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) also fell.
Tools stocks moved as a group
Charles River was not alone. A cluster of life-science tools and equipment names rallied together. Thermo Fisher Scientific (NYSE:TMO) and Danaher (NYSE:DHR) climbed, while Illumina (NASDAQ:ILMN) jumped, according to market data.
The group-wide strength was the clearest backdrop for the move.
Charles River provides research models and outsourced lab services that drug developers use in early-stage and safety testing before medicines reach human trials. That makes it a bellwether for spending on drug research. Investors often treat the tools group as a basket, buying or selling the names together as views on biotech and pharma budgets shift.
Records for tech, pressure from yields
The wider market finished higher. The Nasdaq Composite rose 286.45 points to a record close of 27,477.31, and the Nasdaq-100 set a record at 31,076.44. The S&P 500 gained 51.23 points to 7,773.95, just shy of its summer record, and the Dow Jones Industrial Average added 90.94 points to 51,267.90.
Advancing S&P 500 stocks outnumbered decliners by 1.7 to 1. Materials was the best-performing sector and communication services came second.
Long-term borrowing costs kept rising, though. The 10-year Treasury Yield climbed to its highest close since 2002. The ISM services survey showed prices paid at their highest since July 2022, a sign that Inflation pressures are building. "The prices index continues to trend markedly higher," said Matthew Martin, senior US economist at Oxford Economics.
On the other side of the ledger, Friday's jobs report showed only 29,000 jobs added in September, well below forecasts. That cut the odds of another Fed rate hike in October to roughly one in four or less, down from better than even a week earlier. JPMorgan chief US economist Michael Feroli said: "It would now take a very strong CPI to make the October meeting live."
Oil also eased, with Brent settling at $100.32 a barrel despite the Strait of Hormuz remaining effectively closed. Brazilian stocks listed in New York soared after the first round of that country's presidential election.
Vaccines in the spotlight too
Elsewhere in health care, investors focused on vaccines. Vaxcyte (NASDAQ:PCVX) soared after reporting late-stage data for its pneumococcal Vaccine candidate, and Moderna (NASDAQ:MRNA) rallied ahead of joining the Nasdaq-100. That added to a sense that Monday's health care trading was about picking specific stories rather than buying the whole sector.
What to watch
For Charles River, the next major checkpoint is its quarterly Earnings report, where investors will look for updates on Demand from drug developers.
For the broader market, the Fed releases minutes from its September meeting on Wednesday, Oct. 7, at 2 p.m. ET. PepsiCo reports on Thursday and Delta Air Lines on Friday, before the big banks kick off earnings season from Oct. 13. The Fed's next policy meeting is Oct. 27–28.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...